Compare Eli Lilly And Co (LLY) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

MSTZ stock trades at $11.49, down 6.2% over the past day, amid a mixed technical backdrop with a bullish moving average signal but neutral oscillators. Key support sits at $11, with resistance at $13. Financial ratios including P/E, P/S, and ROE are unavailable, limiting fundamental clarity. Recent news highlights ETF performance trends but lacks direct company updates.

The outlook remains uncertain due to incomplete financial data; upside potential hinges on positive earnings surprises or guidance, while risks include weak fundamentals and market volatility. Investors require verified financials to assess valuation and growth prospects accurately.